L&G Pharma Breakthrough UCITS ETF (EUR) | BIOTRegistreer u om de ratings zichtbaar te maken |
Hoe heeft dit fonds gepresteerd? | 30-04-2024 |
Ontwikkeling van EUR 1000 (EUR) | Uitgebreide Grafiek |
Fonds | 17,1 | 4,8 | -2,6 | -13,6 | -7,9 | |
+/-Cat | -2,1 | 7,9 | 10,2 | -14,6 | -5,6 | |
+/-Idx | -8,7 | -2,1 | 0,5 | -23,5 | -15,9 | |
Categorie: Aandelen Sector Biotechnologie | ||||||
Categorie Benchmark: Morningstar Gbl Biotechnolo... |
Kerngegevens | ||
slotkoers 01-05-2024 | EUR 8,70 | |
Rendement 1 Dag | 0,00% | |
Morningstar Categorie™ | Aandelen Sector Biotechnologie | |
Vestigingsland | Ierland | |
Beurs | EURONEXT AMSTERDAM | |
ISIN | IE00BF0H7608 | |
Grootte Fonds (Mil) 01-05-2024 | USD 18,27 | |
Grootte Fondsklasse (Mil) 01-05-2024 | USD 18,27 | |
Lopende Kosten Factor 14-02-2024 | 0,49% |
Beleggingsdoelstelling: L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT |
The investment objective of the Fund is to provide exposure to bio-technology companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing primarily in a portfolio of equity securities that, as far as possible and practicable, consists of the component securities of the Index in similar proportions to their weightings in the Index and may have exposure to or invest directly up to 20% of its Net Asset Value in shares issued by the same body, which limit may be raised to 35% for a single issuer in exceptional market conditions, including (but not limited to) circumstances in which such issuer occupies a dominant market position. |
Returns | |||||||||||||
|
Management | ||
Naam manager Aanvangsdatum | ||
- - | ||
Oprichtingsdatum 18-01-2018 |
Advertentie |
Categorie Benchmark | |
Benchmark van het fonds | Benchmark Morningstar |
Solactive Pharma Breakthrough V NR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Waar belegt het fonds in? L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT | 01-05-2024 |
|
|
Top 5 posities | Sector | % |
SciClone Pharmaceuticals (Holdin... | Gezondheidszorg | 3,32 |
AstraZeneca PLC ADR | Gezondheidszorg | 2,91 |
Ipsen SA | Gezondheidszorg | 2,72 |
United Therapeutics Corp | Gezondheidszorg | 2,70 |
Swedish Orphan Biovitrum AB | Gezondheidszorg | 2,53 |
Toename Afname Nieuw t.o.v. vorige portefeuille | ||
L&G Pharma Breakthrough UCITS ETF (EUR) | BIOT |